Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 776-790

  Bielack, Stefan S ^a   Kempf Bielack, Beate ^a   Delling, Günter ^a   Exner, G Ulrich ^a   Flege, Silke ^a   Helmke, Knut ^a   Kotz, Rainer ^a   Salzer Kuntschik, Mechthild ^a   Wemer, Matthias ^a   Winkelmann, Winfried ^a   Zoubek, Andreas ^a   Jürgens, Heribert ^a   Winkler, Kurt ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0036467661     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.776     Document Type: Article

References (61)

1. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity
2. Osteogenic sarcoma: Eighty-percent, three-year, disease-free survival with combination chemotherapy (T-7)
3. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
4. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study
5. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the Childrens Cancer Study Group
6. Weekly highdose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/the Children's Hospital-study III
7. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response
8. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation
9. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin
10. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience
11. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup
12. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high dosis of methotrexate followed by cisplatin and doxorubicin
13. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group
14. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup
15. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
16. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienen
17. Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren
18. Nonparametric estimation from incomplete observations
19. Evaluation of survival data and two new rank order statistics arising in its consideration
20. Regression models and life-tables
21. High grade surface osteosarcoma: A clinicopathologic study of 46 cases
22. Common musculoskeletal tumors of childhood and adolescence
23. Underrrepresentation of patients 65 years of age or older in cancer-treatment trials
24. Prognostic factors in osteosarcoma: A critical review
25. Tumor size and prognosis in aggressively treated osteosarcoma
26. Prognostic factors in bone sarcomas
27. Kooperative Osteosarkomstudie COSS-77: Ergebnisse nach über 4 Jahren
28. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy
29. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities
30. Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome
31. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma
32. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
33. Expression of HER2/erbB-2 correlates with survival in osteosarcoma
34. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life
35. Prognostic factors in osteosarcoma
36. Report of the EORTC-SIOP trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation
37. Primary bone-forming tumours and their relationship to skeletal growth
38. Prolonged follow-up of extremity osteosarcoma: Results from the European Osteosarcoma Intergroup
39. Osteosarcoma of the pelvis
40. Osteosarcoma of the pelvis: Oncologic results of 40 patients
41. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
42. Osteosarcoma of the extremities with synchronous lung metastases: Long-term results in 44 patients treated with neoadjuvant chemotherapy
43. Delay in diagnosis of high-grade osteosarcoma of the extremities: Has it any effect on the stage of disease?
44. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin
45. Second malignant neoplasms in children: An update from the Late Effects Study Group
46. Incidence of second primary tumors among childhood cancer survivors
47. Zweitmalignome nach malignen erkrankungen im kindesalter
48. Osteogenic sarcoma of bones and soft tissues in older persons: A clinicopathologic analysis of 117 patients older than 60 years
49. Combined modality treatment for osteosarcoma occurring as a second malignant disease
50. Interval between symptom onset and diagnosis of pediatric solid tumors
51. Prognostic factors in osteosarcomas: A regression analysis
52. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma
53. No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for non-metastatic osteogenic sarcoma (OGS): Preliminary results of randomized Pediatric Oncology Group (POG) trial 8651
54. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma
55. Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence
56. Malignant tumor of the distal part of the femur or the proximal part of the tibia: Endoprosthetic replacement or rotationplasty-Functional outcome and quality-of-life measurements
57. Targeted radiotherapy of osteosarcoma using Sm-153-EDTMP: A new promising approach
58. High-activity Samarium-153-EDTMP therapy in unresectable osteosarcoma